Recent Articles

• 
  IT/Medical

  National Cancer Center Proposes Lung Cancer Treatment Strategy

  Dr. Han Ji-yeon, Dr. Kim Sun-shin, and Dr. Park Chan-i from the National Cancer Center research team (from left). Provided by the National Cancer CenterDr. Han Ji-yeon (Department of Treatment Resistance Research), Dr. Kim Sun-shin, and Dr. Park Chan-i (Department of Targeted Therapy Research) from

  2025.09.10
• 
  Medical / Bio

  Samsung Biologics Signs KRW 1.8 Trillion CMO Deal

  Samsung Biologics HeadquartersSamsung Biologics announced on the 9th through a disclosure that it has signed a contract manufacturing organization (CMO) agreement worth KRW 1.8001 trillion (USD 1.29464 billion) with a U.S.-based pharmaceutical company. This is the second-largest contract following t

  2025.09.09
• 
  Medical / Digital Healthcare

  Daewon Pharmaceutical Revamps Platform to Enhance Communication

  Daewon Pharmaceutical announced on the 8th that it has revamped its medical information exchange platform for healthcare professionals, 'Daewon D-Talks', to 'Daewon D-Talks Re:born' on the occasion of its 4th anniversary since service launch. Since its debut in 2022, Daewon D-Talks has established i

  2025.09.08
• 
  Medical / Vaccine

  HK InnoN, Pfizer Korea Expand COVID-19 Vaccine Supply Partnership

  2025.09.05
• 
  New Drug Development / Medical

  GC Green Cross' Sanfilippo Drug Gains Rare Status

  GC Green Cross HeadquartersGC Green Cross announced on the 5th that its self-developed candidate for the treatment of Sanfilippo Syndrome Type A, 'GC1130A', has been designated as an orphan drug by the Ministry of Food and Drug Safety (MFDS) following the U.S. Food and Drug Administration (FDA) and

  2025.09.05
• 
  IT / Medical

  Celltrion Expands Asian Market Share, Boosts K-Bio Status

  Celltrion Plant 2 OverviewThe growth potential of the Asian pharmaceutical and bio market is being highlighted, drawing increased interest from domestic companies. Celltrion, which has focused on advanced markets such as the United States and Europe, is now also targeting the Asian region. Notably,

  2025.09.05
• 
  Investment

  SC Bio Secures KRW 14 Billion Series B Funding

  Bio startup SC Bio has secured KRW 14 billion in Series B funding. Provided by SC BioBio startup SC Bio announced on the 4th that it has secured KRW 14 billion in Series B funding. This round saw new participation from several institutions, including △Union Investment Partners △Hyundai Technology In

  2025.09.04
• 
  Medical / Pharmaceutical

  Celltrion Boosts Prescriptions in Oceania with Strategy

  Celltrion is launching the autoimmune disease treatment 'Stelkimab' (ingredient name: ustekinumab) and the allergy treatment 'Omriclo' (omalizumab) in Australia, intensifying its market penetration efforts. The company plans to maximize growth by strengthening its portfolio in the Oceania region, in

  2025.09.04
• 
  IT / Medical AI

  Lunit Exports AI Breast Cancer Solution to Spain

  Lunit, a medical artificial intelligence (AI) company, announced on the 2nd that it will exclusively supply its AI solutions to the regional government breast cancer screening program operated by the Valencian Community in Spain. Through this contract, Lunit will provide its self-developed mammograp

  2025.09.03
• 
  New Drug Development / Medical

  AI-Driven Bio Innovation: Rare Disease Prediction, Drug Development

  2025.09.01